SUMMARY Sera from 15 patients with the Zollinger-Ellison syndrome were subjected to gel filtration on Sephadex G-50 superfine columns (10 x 2000 mm). The concentration of gastrin in the effluent was determined by a sensitive radioimmunoassay.
gastrin I constituted 9.5 ± 1.3 (mean ± SEM) %. (4) Component IV ('minigastrin') was eluted immediately before the salt peak and constituted 5.6 ± 1.4 (mean ± SEM) %. In one serum only components I and II were present. After incubation with trypsin all immunoreactivity in components I and II was converted to heptadecapeptide-like gastrins.
The findings suggest that immunoreactive gastrin in serum from Zollinger-Ellison patients is circulating in at least four components of different molecular size.
Yalow and Berson have shown (1970, 1971, and 1972) that plasma from patients with the ZollingerEllison syndrome contains up to three components of immunoreactive gastrin. The major fraction of immunoreactive gastrin was a component with an estimated molecular weight of 7000, named 'basic' or 'big' gastrin. A small component showed chromatographic and electrophoretic characteristics corresponding to those of the heptadecapeptide gastrin of Gregory and Tracy (1964) (Rehfeld, 1972 The columns were calibrated with 1251-albumin, 22Na, monocomponent human insulin, porcine proinsulin, synthetic human gastrin I, and highly purified porcine gastrin 1I. Furthermore 1251-albumin, insulin, proinsulin, and 22Na were added to each serum sample before application to the column for the internal standardization.
Serum samples of 1.0 ml were incubated for 30 minutes with 1.0 ml of a solution of trypsin (1 mg per ml 025 M sodium phosphate, pH 7). After incubation the mixture was applied to the Sephadex G-50 superfine columns.
RADIOIMMUNOANALYSIS
Gastrin was measured with a radioimmunoassay as previously described (Rehfeld, Stadil, and Rubin, 1972) . The accuracy of the assay in determination of gastrin in Zollinger-Ellison sera is illustrated by the dilution experiments shown in figure 1.
Immunoreactive insulin was measured by a wickchromatographic assay (0rskov, 1967 as the heptadecapeptide gastrin I. A small peak was eluted immediately before the salt peak (component IV).
The distribution of the gastrin immunoreactivity in the individual peaks varied individually (see 9.7 ± 4.7 (mean ± SD) % was found in component I. In most sera component II constituted most of the immunoreactivity, 57.8 ± 15.9% (mean of all sera ± SD). Peaks 1 and 2 in component Ill contained 17.4 and 9.5% of the immunoreactivity respectively; and 5.6% was found in component IV. In one serum only components I and II were present. Examples of different elution patterns are shown in figures 2 and 3.
After incubation with trypsin all immunoreactivity from components I and II in all sera was found in the two first peaks in component III as illustrated in figure 4 .
Discussion
The present study has shown that immunoreactive gastrin in serum from Zollinger-Ellison patients 3 emerges by Sephadex gel filtration in fourcomponents. The three components have been described previously in serum from normal subjects and from patients with pernicious anaemia (Rehfeld, 1972 appeared heterogenous, but it was poorly defined (Rehfeld, 1972) . The employment of Sephadex G-50 superfine columns of the double length afforded a resolution of component III in three peaks. The first two of these peaks were eluted as the heptadecapeptides gastrins II and I respectively, and after incubation with trypsin all immunoreactivity in components I and II was found in the two heptadecapeptide-like peaks. The small component IV was probably also present in normal subjects and patients with pernicious anaemia, but could not be clearly separated from component III due to the less sensitive fractionation procedure employed previously. Gregory and Tracy (1972) recently isolated two pairs of gastrin from Zollinger-Ellison tumour tissue. The gastrins were identified biologically. The 'big' pair corresponded to the immunologically defined 'big' gastrin of Yalow and Berson (1970) and component II presented here. The 'small' pair corresponded to heptadecapeptide gastrins I and II in accordance with the two peaks of component III described in the present study. In addition to this pair of little gastrins Gregory and Tracy (1972) noted a third small peak of gastrin. Purification and amino-acid analysis have revealed that this peak is a tridecapeptide lacking the four N-terminal residues of the heptadecapeptide gastrins (Gregory, personal communication) . It is possible that this 'minigastrin' corresponds to the small peak eluted immediately before the salt peak (component IV) as suggested by Gregory (personal communication 
